Goldfinch Bio

Goldfinch Bio is the operator of a drug discovery company that aims to research and develop therapeutic targets for kidney diseases. The company’s drugs are based on segmental glomerulosclerosis, which was developed by leveraging advances in stem cell science to enable healthcare professionals to treat kidney diseases.Goldfinch Bio's lead candidate product, GFB-887, is a TRPC5 ion channel inhibitor, expected to enter Phase 2 clinical trials in mid-2020 for the treatment of kidney diseases. Goldfinch Bio has also developed GFB-024, a peripherally restricted cannabinoid receptor 1 (CB1) reverse agonist monoclonal antibody, for the treatment of rare and metabolic kidney diseases, with an Investigational New Drug (IND) application anticipated to be filed in 2021.